Prognose

Køb	0
Behold	5
Sælg	0

Nyheder Til nyhedsfeedet

Silverback Therapeutics hits 52-week high after strong price surge

Shares of Silverback Therapeutics reached a new 52-week high at $18.59, marking a year-over-year increase of 112.46%. The biotechnology company is benefiting from investor optimism, progress in its clinical pipeline, and a solid financial position. Analysts see further upside potential, while the company's market capitalization now stands at $1.81 billion. » Mere på de.investing.com
Safety Shot completes acquisition of Yerbae Brands and expands product portfolio

Safety Shot, Inc. has completed the acquisition of Yerbae Brands Corp. through a court-approved plan of arrangement. Following the transaction, Safety Shot shareholders hold approximately 81.64% and former Yerbae shareholders about 18.36% of the merged company. Safety Shot also plans to expand its product portfolio to include nootropics and sleep aids, and has entered into a debt settlement agreement with Silverback Capital Corporation. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde SILVERBACK THERAP. -,0001 Aktie en omsætning på 29,49 mio. € og et nettoresultat på -54,62 mio. €

(EUR)	juni 2026	YoY
Omsætning	29,49 mio.	121,16 %
Bruttofortjeneste	0	-
Nettoresultat	-54,62 mio.	43,44 %
EBITDA	-53,86 mio.	42,32 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	476,95 mio. €
Antal aktier	93,77 mio.
Højeste/laveste i 52 uger	6,54 € - 2,43 €
Udbytte	Nej
Beta	0,00
P/E (PE Ratio)	-2,06
PEG (PEG Ratio)	0,02
K/I (PB Ratio)	35,72
P/S (PS Ratio)	3,82

Virksomhedsprofil

Silverback Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das gewebebezogene Therapeutika für die Behandlung von chronischen Virusinfektionen, Krebs und anderen schweren Krankheiten entwickelt. Das Unternehmen bietet SBT8230 zur Behandlung chronischer Hepatitis-B-Virusinfektionen an, indem es eine antivirale Immunantwort durch gezielte TLR8-Aktivierung in der Leber auslöst. Silverback Therapeutics, Inc. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in Seattle, Washington.

Navn	SILVERBACK THERAP. -,0001 Aktie
CEO	Peter A. Thompson
Hjemsted	Seattle, wa USA
Websted	silverbacktx.com
Sektor	Materialer
Branche	Kemikalier
Børsnotering	03.12.2020
Medarbejdere	90